Fraud suit against Novartis, GSK wrapping up; Equity firms reconsider Indian deals

> Attorneys are set to begin closing arguments in the trial of the state of Alabama's Medicaid fraud lawsuit against Novartis and GlaxoSmithKline. Report

> In the wake of the recent Ranbaxy-Daiichi deal, private equity firms are treading a more cautious path in their approach towards investments in the fast-growing Indian drug companies. Report

> Galapagos said its service division BioFocus DPI will provide compound management and related services to Sepracor for about $1.5 million over three years. Report

> Watson Pharmaceuticals launched an authorized generic of Solvay Pharmaceuticals' nausea treatment Marinol. Report

> Dermatology specialist Stiefel Laboratories' buyout of a New Jersey-based competitor promises to increase its product portfolio and hike its Atlanta-area workforce by about 10 percent. Report

> New Hampshire Attorney General Kelly Ayotte is pushing for a central database to track commonly abused prescription drugs such as stimulants, painkillers and muscle relaxants. Report

> There's more bad news for the U.K.'s drug development industry. Pfizer, Roche and Merck Serono have all decided to cut back on clinical research there, according to the Financial Times. Report

> Life science supplier Millipore is giving a $3.4 million boost to its St. Charles, Missouri facility, which is the headquarters for its drug discovery business unit. Report

> GlaxoSmithKline is ending its six-year-long collaboration with Exelixis in October. Report

> Canada's biotech sector is growing, but the country is struggling to find enough "job-ready" candidates. Canada report

And Finally... Think you make your own choices? Think again, new brain research shows. Report